This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Medullary hypoplasia / Aplastic anaemia골수형성저하

ICD-10: D61.9 | Synonyms: medullary hypoplasia, Aplastic anaemia NOS, aplastic anemia (unspecified)

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early descriptions

The concept of aplastic anaemia began when Paul Ehrlich in 1888 first described a patient with severe anemia, leukopenia and fatty infiltration of the bone marrow. He named this condition "aplastische Anämie" and emphasized that it was a state of overall loss of bone marrow function. The clinical concept was later established as Cabot (1904) and Hunter (1907) reported similar cases.

Differentiation of the concept of medullary hypoplasia

Until the early 20th century, aplastic anemia and medullary hypoplasia were not strictly distinguished and were used interchangeably. Classification of a state of reduced cellularity (hypoplasia), as opposed to complete aplasia, as a separate concept began after the 1950s–1960s, when bone marrow histopathology research advanced. As measurement of bone marrow cellularity became possible with the standardization of bone marrow biopsy techniques, the spectrum of hypoplastic and aplastic states began to be understood systematically.

Advances in immunosuppressive therapy

In the 1970s, the treatment paradigm shifted when Thomas et al. succeeded in treating aplastic anemia with allogeneic HSCT. In 1976, immunosuppressive therapy with antithymocyte globulin (ATG) was introduced, providing an effective treatment alternative for patients in whom HSCT was not possible. Subsequently, combination with cyclosporine A (1984) greatly improved the response rate to immunosuppressive therapy.

Status in Korea

In Korea, systematic research on and treatment of aplastic anemia began in the 1980s. Domestic diagnostic criteria and treatment guidelines were established mainly by the Korean Society of Hematology, and Korea has reported world-class results in the field of hematopoietic stem cell transplantation.

2. Causes

Autoimmune mechanism

The most important cause of medullary hypoplasia/aplastic anemia is destruction of hematopoietic stem cells (HSCs) by an autoimmune mechanism. Activated T cells (mainly CD8+ cytotoxic T cells) target and attack hematopoietic stem cells and secrete cytokines such as IFN-γ and TNF-α, inducing hematopoietic stem cell death. About 70–80% of acquired aplastic anemia is estimated to be due to an autoimmune mechanism.

Drugs and toxic substances

Chloramphenicol, sulfonamides, NSAIDs, anticonvulsants (phenytoin, carbamazepine), antithyroid drugs (propylthiouracil, methimazole), gold preparations and antirheumatic drugs (D-penicillamine) can cause bone marrow toxicity. Chemicals such as benzene and organic solvents are also important causes. Bone marrow suppression can occur after radiation exposure.

Viral infection

Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus B19, hepatitis A virus and non-A non-B non-C hepatitis virus are associated with bone marrow suppression. Hepatitis-associated aplastic anaemia is a particularly important clinical form in Asian adolescents.

Congenital causes

Inherited bone marrow failure syndromes such as Fanconi anaemia, Diamond-Blackfan anaemia and dyskeratosis congenita are congenital causes of medullary hypoplasia.

Idiopathic

Idiopathic aplastic anemia, in which the cause cannot be clearly identified, accounts for about 50–70% of all cases. In these cases too, an autoimmune mechanism is presumed to underlie the disease.

3. Genetics

HLA association

In acquired aplastic anemia, an association with the HLA-DR2 (HLA-DRB1*15:01, HLA-DRB1*15:02) alleles has been reported, suggesting that an immunogenetic predisposition is involved in disease susceptibility. The frequency of HLA-DRB1*15:01 carriage is particularly high in Asian patients.

Genetics of inherited bone marrow failure syndromes

Somatic mutations and PNH clones

Somatic mutations such as PIGA, BCOR, BCORL1, DNMT3A and ASXL1 are found in some patients with aplastic anemia. PIGA variants are associated with paroxysmal nocturnal hemoglobinuria (PNH) clones and can progress to aplastic anemia-PNH syndrome. In about 30–35% of patients, telomere length is significantly shorter than expected for age.

4. General epidemiology

Worldwide prevalence

The annual incidence of aplastic anemia is about 2–3 per 1 million in Western countries and relatively high in East Asia (Korea, Japan, China), at about 5–7 per 1 million. Proposed causes of this regional difference include genetic predisposition (HLA allele distribution), environmental factors (benzene exposure, patterns of viral infection) and differences in access to medical care.

Age distribution

A bimodal age distribution of onset is characteristic. The first peak is in adolescents and young adults aged 15–25 years, and the second peak is in older adults aged 60 years and older. In children, the proportion of congenital causes such as Fanconi anemia is high.

Status in Korea

In Korea, about 400–500 new patients with aplastic anemia are estimated to occur each year. According to data from the Korean Society of Hematology, the results of active treatment for patients with severe aplastic anemia have improved, with 5-year survival reaching 70–80%. Hepatitis-associated aplastic anemia accounts for about 5–10% of all patients, a higher proportion in Asia than in Western countries.

5. Pathophysiology

Mechanism of hematopoietic stem cell destruction

In acquired aplastic anemia, autoreactive T cells recognize autoantigens on the surface of hematopoietic stem cells via HLA molecules. Activated CD8+ cytotoxic T cells directly destroy hematopoietic stem cells through the perforin/granzyme pathway and the Fas-FasL pathway. CD4+ T cells secrete IFN-γ, TNF-α and others, inducing apoptosis of hematopoietic stem cells.

Abnormalities of the bone marrow microenvironment

Dysfunction of the bone marrow microenvironment, composed of stromal cells, endothelial cells, adipocytes and others, further suppresses hematopoiesis. Production of hematopoiesis-promoting cytokines such as stem cell factor (SCF), thrombopoietin (TPO) and G-CSF is reduced.

Role of PNH clones

Small PNH clones carrying PIGA mutations are found in about 50% of patients with aplastic anemia. These clones lack GPI-anchored proteins (CD55, CD59) and are therefore vulnerable to complement activation, but they are understood to maintain residual hematopoiesis by surviving through partial evasion of immune attack.

6. Symptoms

Anemia-related symptoms

Fatigue, lethargy, exertional dyspnea, headache and dizziness are the most common initial symptoms. When anemia progresses gradually, patients may adapt to the symptoms and diagnosis may be delayed. Pallor, palpitations and dyspnea at rest are symptoms of severe anemia.

Symptoms related to thrombocytopenia

Skin petechiae, purpura, gum bleeding, nosebleeds (epistaxis), heavy menstrual bleeding (in women) and easy bruising occur. In severe thrombocytopenia there is a risk of internal bleeding (gastrointestinal bleeding, cerebral hemorrhage).

Symptoms related to leukopenia

Recurrent or persistent infections due to neutropenia are characteristic. Fever, oral ulcers, pneumonia and sepsis are the main infectious complications. Fungal infections (invasive aspergillosis, candidiasis) are life-threatening in patients with severe neutropenia.

7. Signs

Physical examination findings

Pallor (conjunctiva, oral mucosa, palms), petechiae, purpura and bruising (ecchymosis) are characteristic. Splenomegaly and lymphadenopathy are generally absent, which is important in differentiation from hematologic malignancies. In Fanconi anemia, physical anomalies such as thumb malformations, patchy skin pigmentation and short stature may be present.

Blood test findings and severity classification

Pancytopenia is characteristic, and the absolute reticulocyte count is markedly reduced. Severity classification according to the international (Camitta) criteria is as follows.

SeverityANCPlateletsReticulocytesBone marrow cellularity
Non-severe (NSAA)>500/μL>20,000/μLNormal or aboveDecreased
Severe (SAA)<500/μL<20,000/μL<20,000/μL<25%
Very severe (vSAA)<200/μL<20,000/μL<20,000/μL<25%

Bone marrow findings

The diagnostic criterion is a reduction of cellularity on bone marrow biopsy to less than 25% (or less than 50% with hematopoietic cells making up less than 30% of the remaining hematopoietic cells). Dysplasia is minimal or absent in aplastic anemia; if dysplasia is prominent, myelodysplastic syndrome (MDS) should be suspected.

8. Screening

General blood tests

A complete blood count (CBC) and reticulocyte count are the primary screening tests. Unexplained pancytopenia (anemia + leukopenia + thrombocytopenia) or a reduction of two or more blood cell lineages requires further evaluation.

Bone marrow examination

Bone marrow aspiration and bone marrow biopsy (trephine biopsy) are central to the diagnosis. They are generally performed at the posterior iliac crest and assess cellularity, presence of dysplasia and degree of fibrosis.

Screening to differentiate inherited bone marrow failure

In children and young adults, a diepoxybutane (DEB) or mitomycin C chromosomal fragility test is performed to differentiate Fanconi anemia. When dyskeratosis congenita is suspected, telomere length measurement (flow-FISH) is performed.

9. Diagnosis

Diagnostic criteria

Diagnosis of aplastic anemia/medullary hypoplasia requires the following conditions: ① reduction of two or more blood cell lineages in peripheral blood ② markedly reduced cellularity on bone marrow biopsy (hypoplasia or aplasia) ③ exclusion of other causes (malignancy, myelodysplasia, congenital bone marrow failure syndromes).

Differential diagnosis tests

Myelodysplastic syndrome (MDS), hypocellular acute myeloid leukemia (hypocellular AML), PNH, large granular lymphocytic leukemia (LGL leukemia), systemic lupus erythematosus and others are differentiated. For this, cytogenetic testing, FISH, bone marrow immunohistochemical staining, flow cytometry and PNH clone analysis (CD55/CD59) are performed.

Molecular genetic testing

Next-generation sequencing (NGS)-based hematologic neoplasm panels are used to analyze somatic mutations such as DNMT3A, ASXL1 and TET2 for differentiation from MDS and clonal hematopoiesis (CHIP). When a congenital bone marrow failure syndrome is suspected, the relevant gene panel test is performed.

10. Treatment

Allogeneic hematopoietic stem cell transplantation (allogeneic HSCT)

In patients with severe or very severe aplastic anemia who are 40 years of age or younger and have an HLA-matched sibling donor, allogeneic HSCT is performed as first-line treatment. It enables fundamental correction of marrow aplasia, and 5-year survival reaches 85–95%. If no HLA-matched sibling donor is available, transplantation from an HLA-matched unrelated donor or an alternative donor (haploidentical HSCT) is considered.

Immunosuppressive therapy (IST)

In patients who are not candidates for HSCT, combination therapy with antithymocyte globulin (ATG) + cyclosporine A + eltrombopag is the standard treatment. Recent clinical studies have confirmed that triple combination of ATG + cyclosporine + eltrombopag yields a better response rate than traditional dual immunosuppression.

Supportive care

Packed red blood cell transfusion (Hb <7 g/dL or when symptomatic), platelet transfusion (platelets <10,000/μL or with bleeding), broad-spectrum antibacterials and antifungals (in neutropenic fever), G-CSF (in neutropenic infection) and folic acid supplementation are given.

11. Prognosis

Survival by treatment

Five-year survival in patients with severe aplastic anemia who undergo HSCT from an HLA-matched sibling donor is 85–95%, and 70–85% with HSCT from an HLA-matched unrelated donor. The overall response rate to ATG + cyclosporine immunosuppressive therapy is about 60–70%, and 10-year survival is 70–80%.

Long-term complications

Long-term complications after immunosuppressive therapy include clonal evolution (transformation to MDS or AML, about 5–15%), emergence of PNH (about 5–10%) and relapse (about 30–40%). The main complications after HSCT are graft-versus-host disease (GVHD), infection and secondary malignancy. Age (better when younger), severity of cytopenia at diagnosis and treatment response affect prognosis.

12. Prevention

Avoidance of causative agents

Occupational exposure to bone marrow-toxic chemicals such as benzene and organic solvents is minimized, and appropriate protective equipment is worn. When using bone marrow-toxic drugs (chloramphenicol, sulfonamides, etc.), unnecessary long-term administration is avoided and blood counts are monitored regularly.

Infection prevention

Vaccination against viral infections (particularly hepatitis viruses) is given. In patients receiving immunosuppressive therapy, PCP prophylaxis (trimethoprim-sulfamethoxazole), antifungal prophylaxis (fluconazole or posaconazole) and CMV surveillance are performed.

Genetic counseling for congenital bone marrow failure

When an inherited cause such as Fanconi anemia, dyskeratosis congenita or Diamond-Blackfan anemia is confirmed, genetic counseling and family screening are performed. Prenatal genetic testing or preimplantation genetic testing can prevent affected births.

13. References

  1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
  2. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
  3. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550.
  4. Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence. Haematologica. 2014;99(10):1574-1581.
  5. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436.
  6. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3):101-122.
  7. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
  8. Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011;4(2):221-230.
  9. Yoshida N, Yagasaki H, Hama A, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011;96(5):771-774.
  10. Kim SY, Lee JW. Aplastic anemia in Korea: evolving treatment strategies and outcomes. Korean J Intern Med. 2019;34(6):1171-1182.
  11. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
  12. Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28(1):55-68.